Garg Abhishek D, More Sanket, Rufo Nicole, Mece Odeta, Sassano Maria Livia, Agostinis Patrizia, Zitvogel Laurence, Kroemer Guido, Galluzzi Lorenzo
Cell Death Research & Therapy (CDRT) Lab, Department of Cellular & Molecular Medicine, KU Leuven University of Leuven, Leuven, Belgium.
Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Oncoimmunology. 2017 Oct 4;6(12):e1386829. doi: 10.1080/2162402X.2017.1386829. eCollection 2017.
The expression "immunogenic cell death" (ICD) refers to a functionally unique form of cell death that facilitates (instead of suppressing) a T cell-dependent immune response specific for dead cell-derived antigens. ICD critically relies on the activation of adaptive responses in dying cells, culminating with the exposure or secretion of immunostimulatory molecules commonly referred to as "damage-associated molecular patterns". Only a few agents can elicit ICD, including some clinically established chemotherapeutics such as doxorubicin, epirubicin, idarubicin, mitoxantrone, bleomycin, bortezomib, cyclophosphamide and oxaliplatin. In this Trial Watch, we discuss recent progress on the development of ICD-inducing chemotherapeutic regimens, focusing on studies that evaluate clinical efficacy in conjunction with immunological biomarkers.
“免疫原性细胞死亡”（ICD）这一表述指的是一种功能独特的细胞死亡形式，它能够促进（而非抑制）针对死亡细胞衍生抗原的T细胞依赖性免疫反应。ICD关键依赖于死亡细胞中适应性反应的激活，最终导致通常被称为“损伤相关分子模式”的免疫刺激分子的暴露或分泌。只有少数药物能够引发ICD，包括一些临床常用的化疗药物，如阿霉素、表柔比星、伊达比星、米托蒽醌、博来霉素、硼替佐米、环磷酰胺和奥沙利铂。在本期“试验观察”中，我们讨论了诱导ICD的化疗方案的最新进展，重点关注结合免疫生物标志物评估临床疗效的研究。
